Ana Slipicevic

1.2k total citations
37 papers, 823 citations indexed

About

Ana Slipicevic is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Ana Slipicevic has authored 37 papers receiving a total of 823 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Molecular Biology, 23 papers in Oncology and 7 papers in Hematology. Recurrent topics in Ana Slipicevic's work include Multiple Myeloma Research and Treatments (7 papers), Melanoma and MAPK Pathways (7 papers) and Peptidase Inhibition and Analysis (5 papers). Ana Slipicevic is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Melanoma and MAPK Pathways (7 papers) and Peptidase Inhibition and Analysis (5 papers). Ana Slipicevic collaborates with scholars based in Norway, United States and Canada. Ana Slipicevic's co-authors include Viví Ann Flørenes, Ben Davidson, Ruth Holm, Anne Katrine Ree Rosnes, Elisabeth Emilsen, Martina L. Skrede, Claes G. Tropé, Mai T. Nguyen, Arild Holth and Per J. Bøhler and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Ana Slipicevic

37 papers receiving 802 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Ana Slipicevic 623 311 152 87 67 37 823
Andrea Ghelli Luserna di Rorà 513 0.8× 303 1.0× 98 0.6× 76 0.9× 73 1.1× 38 735
Anja Deutzmann 608 1.0× 230 0.7× 189 1.2× 143 1.6× 46 0.7× 15 860
Vanessa Baeriswyl 728 1.2× 452 1.5× 190 1.3× 150 1.7× 52 0.8× 14 1.1k
Shilpi Arora 680 1.1× 260 0.8× 262 1.7× 60 0.7× 49 0.7× 31 948
Megan J. Bywater 1.1k 1.7× 278 0.9× 149 1.0× 115 1.3× 73 1.1× 24 1.3k
Susan E. Morgan-Lappe 827 1.3× 406 1.3× 190 1.3× 171 2.0× 60 0.9× 20 1.1k
Shengyan Xiang 765 1.2× 273 0.9× 109 0.7× 58 0.7× 61 0.9× 25 919
Alice Agliano 431 0.7× 429 1.4× 246 1.6× 100 1.1× 43 0.6× 16 810
Gaynor Davies 576 0.9× 351 1.1× 255 1.7× 87 1.0× 46 0.7× 22 1.0k
Kym L. Stanley 588 0.9× 310 1.0× 123 0.8× 107 1.2× 39 0.6× 10 893

Countries citing papers authored by Ana Slipicevic

Since Specialization
Citations

This map shows the geographic impact of Ana Slipicevic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ana Slipicevic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ana Slipicevic more than expected).

Fields of papers citing papers by Ana Slipicevic

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ana Slipicevic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ana Slipicevic. The network helps show where Ana Slipicevic may publish in the future.

Co-authorship network of co-authors of Ana Slipicevic

This figure shows the co-authorship network connecting the top 25 collaborators of Ana Slipicevic. A scholar is included among the top collaborators of Ana Slipicevic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ana Slipicevic. Ana Slipicevic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Miettinen, Juho J., Toni-Karri Pakarinen, Mikko Manninen, et al.. (2022). Growth Response and Differentiation of Bone Marrow-Derived Mesenchymal Stem/Stromal Cells in the Presence of Novel Multiple Myeloma Drug Melflufen. Cells. 11(9). 1574–1574. 5 indexed citations
2.
Miettinen, Juho J., Romika Kumari, Gunnhildur Ásta Traustadóttir, et al.. (2021). Aminopeptidase Expression in Multiple Myeloma Associates with Disease Progression and Sensitivity to Melflufen. Cancers. 13(7). 1527–1527. 39 indexed citations
3.
Byrgazov, Konstantin, Thomas Lind, Annica J. Rasmusson, et al.. (2021). Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes. Bone Reports. 15. 101098–101098. 3 indexed citations
4.
Schepsky, Alexander, Gunnhildur Ásta Traustadóttir, Sævar Ingþórsson, et al.. (2020). Melflufen, a peptide‐conjugated alkylator, is an efficient anti‐neo‐plastic drug in breast cancer cell lines. Cancer Medicine. 9(18). 6726–6738. 9 indexed citations
5.
Poźniak, Joanna, Jérémie Nsengimana, Mark Harland, et al.. (2019). MX 2 is a novel regulator of cell cycle in melanoma cells. Pigment Cell & Melanoma Research. 33(3). 446–457. 10 indexed citations
6.
Nymoen, Dag André, Ana Slipicevic, Arild Holth, et al.. (2016). MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma. Human Pathology. 54. 74–81. 8 indexed citations
7.
Emilsen, Elisabeth, Karianne G. Fleten, Birgit Engesæter, et al.. (2015). Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma. BMC Cancer. 15(1). 462–462. 40 indexed citations
8.
9.
Slipicevic, Ana, et al.. (2014). Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions. Gynecologic Oncology. 135(1). 118–124. 64 indexed citations
10.
Slipicevic, Ana, Anne Katrine Ree Rosnes, Elisabeth Emilsen, et al.. (2013). Low-dose anisomycin sensitizes melanoma cells to TRAIL induced apoptosis. Cancer Biology & Therapy. 14(2). 146–154. 14 indexed citations
11.
Slipicevic, Ana, Rajasekharan Somasundaram, Katrin Sproesser, & Meenhard Herlyn. (2013). Isolation of Melanoma Cell Subpopulations Using Negative Selection. Methods in molecular biology. 1102. 501–512. 4 indexed citations
12.
Slipicevic, Ana, Ruth Holm, Elisabeth Emilsen, et al.. (2012). Cytoplasmic BRMS1 expression in malignant melanoma is associated with increased disease-free survival. BMC Cancer. 12(1). 73–73. 26 indexed citations
13.
Slipicevic, Ana & Meenhard Herlyn. (2012). Narrowing the knowledge gaps for melanoma. Upsala Journal of Medical Sciences. 117(2). 237–243. 12 indexed citations
14.
Holm, Ruth, et al.. (2012). High Expression of Wee1 Is Associated with Poor Disease-Free Survival in Malignant Melanoma: Potential for Targeted Therapy. PLoS ONE. 7(6). e38254–e38254. 122 indexed citations
15.
Slipicevic, Ana, et al.. (2009). Biological effects induced by insulin‐like growth factor binding protein 3 (IGFBP‐3) in malignant melanoma. International Journal of Cancer. 126(2). 350–361. 19 indexed citations
16.
17.
Davidson, Ben, Rivka Hadar, Ana Slipicevic, et al.. (2007). Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Human Pathology. 39(1). 87–95. 91 indexed citations
18.
Torlakovic, Emina, Ana Slipicevic, Chris Robinson, et al.. (2006). Pax-5 Expression in Nonhematopoietic Tissues. American Journal of Clinical Pathology. 126(5). 798–804. 44 indexed citations
19.
Jørgensen, Kjersti, Martina L. Skrede, Véronique Cruciani, et al.. (2005). Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2. Biochemical and Biophysical Research Communications. 329(1). 266–274. 27 indexed citations
20.
Slipicevic, Ana, Ruth Holm, Mai T. Nguyen, et al.. (2005). Expression of Activated Akt and PTEN in Malignant Melanomas. American Journal of Clinical Pathology. 124(4). 528–536. 71 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrea Ghelli Luserna di Rorà Breakdown of academic impact, for papers by Anja Deutzmann Breakdown of academic impact, for papers by Vanessa Baeriswyl Breakdown of academic impact, for papers by Shilpi Arora Breakdown of academic impact, for papers by Megan J. Bywater Breakdown of academic impact, for papers by Susan E. Morgan-Lappe Breakdown of academic impact, for papers by Shengyan Xiang Breakdown of academic impact, for papers by Alice Agliano Breakdown of academic impact, for papers by Gaynor Davies Breakdown of academic impact, for papers by Kym L. Stanley
Rankless by CCL
2026